Premium
The impact of Ets‐1 oncoprotein and human endoglin ( CD 105) on the recurrence of non‐melanoma skin cancers
Author(s) -
Chrisostomidis Chrisostomos,
Konofaos Petros,
Karypidis Dimitrios,
Lazaris Andreas,
Kostakis Alkiviadis,
Papadopoulos Othon
Publication year - 2015
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/ijd.12891
Subject(s) - medicine , endoglin , basal cell carcinoma , melanoma , immunohistochemistry , skin cancer , oncology , pathology , basal cell , dermatology , cancer , cancer research , stem cell , genetics , cd34 , biology
Background The aim of this study was to investigate if the expression of CD 105 and Ets‐1 was predictive of aggressive biologic behavior of non‐melanoma skin cancers ( NMSC ) and to evaluate indicators of local recurrence. Patients and methods A total of 144 patients with NMSC were included in the current study. Surgical specimens were independently examined for diagnosis confirmation and immunohistochemical expression of Ets‐1 and CD 105 by two dermatopathologists. Results The most common tumor type was basal cell carcinoma ( n = 76), followed by squamous cell carcinomas ( SCC ) ( n = 65). The most common anatomic location was the head and neck area ( n = 115). The follow‐up was ˃2 years in all examined cases. A statistically significant correlation was found between tumor local recurrence and age ( P = 0.03), Ets‐1 expression ( P ˂ 0.0001) and CD 105 expression ( P ˂ 0.0001). Conclusions Our data confirm that both Ets‐1 and CD 105 show promise as prognostic markers for local recurrence of NMSC . However, this statement is made with caution, and additional studies, with larger populations, are necessary to examine the correlation between these two markers and local recurrence. A better understanding of the pathogenesis of local recurrence in primary NMSC may result in potential therapeutic interventions.